Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
THORAZINE (brand name for chlorpromazine) is an oral extended-release small-molecule antipsychotic approved in 1957, representing a foundational first-generation antipsychotic class. While specific indications are not detailed in available data, first-generation antipsychotics are typically used for schizophrenia, bipolar disorder, and severe agitation. The drug works by blocking dopamine receptors in the central nervous system.
With LOE approaching and competitive pressure at 30%, teams are likely consolidating and focusing on defending core indications or supporting transition to next-generation compounds.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on THORAZINE offers limited career growth potential given its LOE approaching status and zero linked job openings. Roles are primarily maintenance-focused, supporting existing patient populations and managing competitive erosion rather than driving innovation or expansion.
Worked on THORAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.